Multiple Myeloma

MULTIPLE MYELOMA NEWS TIPS & FEATURES

Early Treatment in Smoldering Myeloma Improves Long-Term Outcomes

February 2nd, 2017

Early Treatment in Smoldering Myeloma Improves Long-Term Outcomes

Use of the treatment combination consisting of Revlimid (lenalidomide) plus dexamethasone during smoldering myeloma appears to significantly improve long-term outcomes for patients. These results were […]


Velcade® Revlimid®/Dexamethasone New Standard of Care for Newly Diagnosed Multiple Myeloma

January 31st, 2017

Velcade® Revlimid®/Dexamethasone New Standard of Care for Newly Diagnosed Multiple Myeloma

The addition of the proteasome inhibitor Velcade® (bortezomib) to the treatment combination Revlimid® (lenalidomide) plus dexamethasone improves survival when used as initial therapy in multiple […]


Scientific Highlights from American Society of Hematology Meeting

January 24th, 2017

Scientific Highlights from American Society of Hematology Meeting

About CAR-T CAR-T, or chimeric antigen receptor T-cells, is a new form of cancer immunotherapy in which a patient’s own T cells are removed and […]


Duration of Blood Storage Does Not Affect Outcomes for Patients Requiring Blood Transfusions

December 1st, 2016

Duration of Blood Storage Does Not Affect Outcomes for Patients Requiring Blood Transfusions

The length of time that blood is stored prior to a blood transfusion, within normal ranges, does not appear to affect mortality among patients requiring […]


Darzalex® Approved for Additional Indications in Multiple Myeloma

November 29th, 2016

Darzalex® Approved for Additional Indications in Multiple Myeloma

The United States Food and Drug Administration (FDA) has approved Darzalex® (daratumumab) for the treatment of multiple myeloma among patients who have received at least […]


HOVON Trial: Autologous Stem Cell Transplant Remains Superior to Novel Agents for Treatment of Multiple Myeloma

October 12th, 2016

HOVON Trial: Autologous Stem Cell Transplant Remains Superior to Novel Agents for Treatment of Multiple Myeloma

A large, comparative, phase III HOVON clinical trial recently confirmed that upfront autologous stem cell transplantation (ASCT) should still be the treatment of choice in […]


Advances offer Promise for Multiple Myeloma Patients

September 1st, 2016

Advances offer Promise for Multiple Myeloma Patients

With a growing number of treatment options, the out­look is improving for patients with this blood cancer. By Mia James Una Wilson initially thought that […]


Darzalex™ Effective in Heavily Pre-Treated Multiple Myeloma

July 7th, 2016

Darzalex™ Effective in Heavily Pre-Treated Multiple Myeloma

The targeted agent Darzalex (daratumumab) produces long-lasting anti-cancer responses among patients with multiple myeloma that has stopped responding to several prior therapies. These results were […]


Ask the Expert: Multiple Myeloma

May 4th, 2016

Ask the Expert: Multiple Myeloma

CancerConnect recently collaborated with The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC – James) to provide you […]


Aplidin® Improves Progression-Free Survival in Multiple Myeloma

April 21st, 2016

Aplidin® Improves Progression-Free Survival in Multiple Myeloma

The addition of the investigative agent Aplidin® (plitidepsin) to dexamethasone appears to significantly reduce the risk of cancer progression or death compared to dexamethasone alone […]


More News →